Alaunos Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for TCRT, updated each market day.
TCRT AI Sentiment
AI sees no strong directional signal for Alaunos Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: May 18, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Alaunos Therapeutics, Inc. Common Stock
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
Sector
Exchange
Market Cap
$6,053,977
Cap Tier
Employees
1
Headquarters
FORT LAUDERDALE, FL
Listed Since
Aug. 24, 2005
Website
TCRT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TCRT Volatility
Alaunos Therapeutics, Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
